{"id":"W4408978966","doi":"10.1016/s1556-0864(25)00205-9","title":"10MO: Preventing moderate to severe dermatologic adverse events in first-line EGFR-mutant advanced NSCLC treated with amivantamab plus lazertinib: Early success of the COCOON trial","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"LG Chem; Plexxikon; European Society for Medical Oncology; Astellas Pharma; EQRx; G1 Therapeutics; MacroGenics; ECOG-ACRIN Cancer Research Group; International Association for the Study of Lung Cancer; BeiGene; Mirati Therapeutics; LAM Therapeutics; Astex Pharmaceuticals; Les Laboratories Pierre Fabre; AstraZeneca; Novocure; Ipsen; Array BioPharma; Jazz Pharmaceuticals; Regeneron Pharmaceuticals; Yonsei University; Pfizer; Incyte; American College of Radiology Imaging Network; Bristol-Myers Squibb; Ignyta; Eli Lilly and Company; American Society of Clinical Oncology; Mersana Therapeutics; Yuhan; Daiichi Sankyo Europe; LEO Pharma; Servier; Gilead Sciences; Sanofi; Amgen","keywords":"Medicine; Adverse effect; Mutant; Dermatology; Oncology; Internal medicine; Genetics","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009687385,0.0006696376,0.001260955,0.0001874686,0.0002129225,0.0009456186,0.0004560472,0.0007584514,0.004469886],"category_scores_gemma":[0.001209142,0.0001932134,0.001517361,0.0002050176,0.0004344559,0.0008151205,0.0003351977,0.002423251,0.0006329347],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007559031,"about_ca_system_score_gemma":0.0007589079,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001043703,"about_ca_topic_score_gemma":0.003655879,"domain_scores_codex":[0.999782,0.0001007752,0.00001072975,0.00003170428,0.00002119725,0.00005361172],"domain_scores_gemma":[0.9995952,0.00009732488,0.00007112052,0.00002177339,0.00002991236,0.0001846564],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6656474,0.006480498,0.004880446,0.001712598,0.002880288,0.0002563935,0.0000930837,0.001216104,0.009924305,0.0009277751,0.01209525,0.2938858],"study_design_scores_gemma":[0.7842627,0.1715019,0.02343873,0.000420148,0.002957058,0.0004719143,0.0001491076,0.002688961,0.00267547,0.0008836921,0.01048369,0.00006663031],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9674777,0.0191274,0.000516096,0.003986752,0.001083223,0.0005823357,0.00108674,0.0002525036,0.00588728],"genre_scores_gemma":[0.986091,0.006597466,0.0007556318,0.002008701,0.000362632,0.0003116442,0.0009612012,0.0000237355,0.002888009],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004469886,"threshold_uncertainty_score":0.0149532,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02016522738120987,"score_gpt":0.3796947738518141,"score_spread":0.3595295464706043,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}